Elizabeth Garrett-Mayer

A phase II pharmacokinetic/pharmacogenetic (PK/PG) study using fixed-dose capecitabine in metastatic breast cancer (MBC).

A. Wolff, N. Davidson, M. Rudek, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements

J. Verweij, H. Gelderblom, E. Garrett-Mayer, 2008, Clinical pharmacology and therapeutics.

Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.

A. Wolff, J. Verweij, S. Baker, 2004, European journal of cancer.